{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:42:37Z","timestamp":1788493357972,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.14283\/jpad.2024.123","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T09:44:51Z","timestamp":1719308691000},"page":"814-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study"],"prefix":"10.1016","volume":"11","author":[{"given":"Dorene M.","family":"Rentz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.123_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer's Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.123_bib2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating Scale (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.123_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/13854046.2015.1119312","article-title":"How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond?","volume":"29","author":"Balsis","year":"2015","journal-title":"Clin Neuropsychol"},{"key":"10.14283\/jpad.2024.123_bib4","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jalz.2011.11.002","article-title":"Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials","volume":"9","author":"Cedarbaum","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.123_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/psp4.12974","article-title":"Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB","volume":"12","author":"Jamalian","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.14283\/jpad.2024.123_bib6","author":"Administration FaD"},{"key":"10.14283\/jpad.2024.123_bib7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.123_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.123_bib9","first-page":"746","article-title":"Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database","volume":"67","author":"O'Bryant","year":"2010","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2024.123_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trci.2018.11.004","article-title":"FDA position statement \u201cEarly Alzheimer's disease: Developing drugs for treatment, Guidance for Industry\u201d","volume":"5","author":"Sabbagh","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2024.123_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.14283\/jpad.2024.123_bib12","series-title":"Administration and Scoring Manual","article-title":"WMS-III, Wechsler Memory Scale-Third Edition","author":"Wechsler","year":"1997"},{"key":"10.14283\/jpad.2024.123_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.14283\/jpad.2024.123_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","article-title":"Solanezumab for the treatment of mild-to-moderate Alzheimer's disease","volume":"8","author":"Imbimbo","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.14283\/jpad.2024.123_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/pst.2285","article-title":"Natural cubic splines for the analysis of Alzheimer's clinical trials","volume":"22","author":"Donohue","year":"2023","journal-title":"Pharm Stat"},{"key":"10.14283\/jpad.2024.123_bib16","article-title":"Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study","volume":"12","author":"Marshall","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2024.123_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.14283\/jpad.2021.8","article-title":"Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data","volume":"8","author":"Amariglio","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.123_bib18","doi-asserted-by":"crossref","first-page":"111c","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.14283\/jpad.2024.123_bib19","article-title":"Building clinically relevant outcomes across the Alzheimer's disease spectrum","volume":"7","author":"Rentz","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2024.123_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2023.0268","article-title":"Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease","volume":"329","author":"Le Guen","year":"2023","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.123_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jama.279.10.751","article-title":"The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics","volume":"279","author":"Tang","year":"1998","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.123_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006239","article-title":"Epidemiology of Alzheimer disease","volume":"2","author":"Mayeux","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.14283\/jpad.2024.123_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of Racial Disparities in Biomarkers for Alzheimer Disease","volume":"76","author":"Morris","year":"2019","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:07:08Z","timestamp":1737338828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2274580724000037"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.123","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}